glp 1 clinical trial GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 therapies are powerful, but

OptumRx, 2026 formulary update and prior authorization criteria In February 2026, OptumRx removed the BMI requirement from its cardiovascular reauthorization criteria for Wegovy, simplifying continued authorization for UHC members using the CV indication

All these companies are at least two years away from regulatory approval and launch

Semaglutide drug monograph

Did you know about gastronomy in Lima

Oct 27: Roches Genentech can add a third indication to Vabysmos label after the FDA signed off on the bispecific antibody to treat macular edemaswellingfollowing retinal vein occlusion (RVO)

Novo Nordisk, the maker of Wegovy, used to have a savings program that lowered the price of Wegovy to $25